1 of 11

METODE EVALUASI EKONOMI:�PARSIAL DAN PENUH

Septiara Putri

Departemen Administrasi dan Kebijakan Kesehatan

Fakultas Kesehatan Masyarakat Universitas Indonesia

2021

2 of 11

Gambaran umum

  • Pengantar
  • Jenis evaluasi ekonomi
  • Evaluasi ekonomi parsial
  • Evaluasi ekonomi penuh
  • Contoh

​

2

3 of 11

3

Jenis-jenis Evaluasi Ekonomi

Source: Drummond et al., 2015

4 of 11

4

Evaluasi Ekonomi

Parsial

5 of 11

Evaluasi Ekonomi (Penuh)

5

6 of 11

Konsep dasar

6

https://www.has-sante.fr/jcms/c_2035665/en/methods-for-health-economic-evaluation

7 of 11

Metode evaluasi ekonomi

    • Berdampingan dengan clinical trial
    • Mengumpulan patient-level data baik biaya dan luaran selama trial berlangsung

Trial based

    • Membandingkan biaya dan konsekuensi dari pilihan keputusan dengan mensintesis informasi dari berbagai sumber dengan menerapkan teknik matematika

Model based

Glick, H. A., Doshi, J. A., Sonnad, S. S., & Polsky, D. (2014). Economic evaluation in clinical trials. OUP Oxford.

Petrou, S., & Gray, A. (2011). Economic evaluation using decision analytical modelling: design, conduct, analysis, and reporting. Bmj, 342, d1766.

​

8 of 11

ICER and Threshold

 

Incremental resources required

Incremental health effect gained

Cost effective?

​

ICER < λ (threshold)

9 of 11

Studi Evaluasi Ekonomi (1)

Economic Evaluation of Cetuximab as adjuvant therapy for metastatic colorectal cancer

​

Method: Cost Utility Analysis (CUA)

Perspective: Societal (direct and indirect costs)

Clinical Effectiveness: Systematic review and meta-analysis

Economic model: Model Based (Markov with three states), Lifetime horizon

Result: ICER/QALY

Sensitivity analysis: deterministic and probabilistic

Threshold used: 1-3 GDP per capita (IDR 140 million)

​

​

​

​

 

FOLFOX

FOLFIRI#

Cetuximab+

FOLFOX

Cetuximab+

FOLFIRI

Costs (IDR in million)

549

501

815

767

Life Years

2.04

2.00

2.18

2.17

QALY

0.97

0.90

1.07

0.99

ICER/LY

1,332

 

1,794

1,565

ICER/QALY

(IDR in million)

670

 

1,814

2,949

10 of 11

Studi Evaluasi Ekonomi (2)

Economic Evaluation of Rituximab and chemotherapy for Non Hodgkin Lymphoma Patients with Sub Type Diffuse Large B Cell (DLBCL)

​

Method: Cost Utility Analysis (CUA)

Perspective: Societal (direct and indirect costs)

Clinical Effectiveness: Systematic review and meta-analysis

Economic model: Model Based (Markov with three states), Lifetime horizon

Result: ICER/QALY

Sensitivity analysis: deterministic and probabilistic

Threshold used: 1-3 GDP per capita (IDR 160 million)

​

​

​

​

 

Rituximab

+CHOP

CHOP

Costs (IDR in million)

1,494

1,341

Life Years

6.39

4.06

QALY

4.18

4.00

ICER/LY

66

 

ICER/QALY (IDR in million)

131

 

11 of 11

TERIMA KASIH

septiaraputri@ui.ac.id

11